/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

S

Susanna V. Ulahannan

Oklahoma State University Oklahoma City(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

258

Papers

3.2K

Citations

25

h-index

47

i10-index

Susanna V. Ulahannan is an academic researcher from Oklahoma State University Oklahoma City. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Colorectal Cancer Treatments and Studies & Cancer, Hypoxia, and Metabolism. The author has an h-index of 25, co-authored 220 publications.

ORCID: 0000-0002-7234-2283

Research Topics

Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies Cancer, Hypoxia, and Metabolism Lung Cancer Treatments and Mutations Peroxisome Proliferator-Activated Receptors

Papers by this author

works

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

2023 · Journal of Hepatology · 57 citations

https://doi.org/10.1016/j.jhep.2023.10.040

Ciro Celsa Giuseppe Cabibbo Claudia Angela Maria Fulgenzi Bernhard Scheiner

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

2024 · Hepatology · 41 citations

https://doi.org/10.1097/hep.0000000000001026

Ciro Celsa Giuseppe Cabibbo Claudia Angela Maria Fulgenzi Salvatore Battaglia

625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications

2024 · Annals of Oncology · 2 citations

https://doi.org/10.1016/j.annonc.2024.08.692

Marwan Fakih Davendra Sohal Justin Call Susanna V. Ulahannan

924MO First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors

2025 · Annals of Oncology · 1 citations

https://doi.org/10.1016/j.annonc.2025.08.1493

Timothy A. Yap N. Lakhani Minal Barve E.P. Hamilton

FIGURE 2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

2024 · 0 citations

https://doi.org/10.1158/2767-9764.25639257

Mark Yarchoan John D. Powderly Bruno R. Bastos Thomas B. Karasic

Supplementary Figure S4 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

2024 · 0 citations

https://doi.org/10.1158/2767-9764.25639242

Mark Yarchoan John D. Powderly Bruno R. Bastos Thomas B. Karasic

Research topics

topics

Cancer Immunotherapy and Biomarkers

Colorectal Cancer Treatments and Studies

Cancer, Hypoxia, and Metabolism

Lung Cancer Treatments and Mutations

Peroxisome Proliferator-Activated Receptors

Chat about Author

Papers

Chat

Click to start Chat